Leflunomide as a cause of collagenous colitis: an entity to consider.
Paulina NúñezRodrigo QueraLilian FloresLuis ContrerasPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2021)
Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.
Keyphrases
- rheumatoid arthritis
- weight loss
- abdominal pain
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- bariatric surgery
- disease activity
- rheumatoid arthritis patients
- peritoneal dialysis
- irritable bowel syndrome
- emergency department
- ultrasound guided
- clostridium difficile
- drug induced
- roux en y gastric bypass
- adipose tissue
- systemic lupus erythematosus
- body mass index
- insulin resistance
- patient reported
- electronic health record